Report cover image

Dementia and Movement Disorder Treatment Market Size, Share, and Outlook, H2-2025 Report- By Application (Movement disorders, Progressive dementia, Progressive dementia with neurological abnormality (PDNA)), By Drug Class (MAO inhibitors, Acetylcholineste

Publisher VPA Research
Published Sep 01, 2025
Length 181 Pages
SKU # VPA20329549

Description

Dementia and Movement Disorder Treatment Market Outlook
The global Dementia and Movement Disorder Treatment Market Size is valued at $21.4 Billion in 2025 and is forecast to reach $35.7 Billion in 2032 at a CAGR of 7.6%.
The Dementia and Movement Disorder Treatment Market continue to remain a steadily growing market and offers lucrative growth opportunities across the industry stakeholders from suppliers to distributors and end-use industries. This comprehensive market research report provides 12-year historic and forecast data on Dementia and Movement Disorder Treatment Market segments across 22 countries from 2021 to 2032. Key segments covered include By Application (Movement disorders, Progressive dementia, Progressive dementia with neurological abnormality (PDNA)), By Drug Class (MAO inhibitors, Acetylcholinesterase inhibitors, Glutamate inhibitors, Others), offering granular insights into performance drivers and emerging patterns. With over 70 tables and charts, the report provides actionable findings based on extensive data modeling and industry surveys.

Dementia and Movement Disorder Treatment Market Insights, 2025
The dementia and movement disorder treatment market in 2025 is shaped by a dual focus on slowing disease progression and improving quality of life in conditions such as Alzheimer’s, Parkinson’s, Lewy body dementia, and Huntington’s disease. Disease-modifying therapies for Alzheimer’s that target amyloid and tau proteins are advancing in post-approval safety monitoring, while novel dopamine pathway modulators for Parkinson’s are extending “on” time and reducing motor fluctuations. Non-pharmacological interventions, including VR-based cognitive stimulation and AI-assisted gait rehabilitation, are gaining traction in specialized care facilities. Digital biomarkers from wearable and at-home monitoring systems are enabling earlier diagnosis and individualized therapy adjustments. Cross-disciplinary clinics are integrating neurology, psychiatry, and physiotherapy to optimize patient outcomes and caregiver support.

Five Trends Shaping the Global Dementia and Movement Disorder Treatment Market in 2025 and Beyond
The global Dementia and Movement Disorder Treatment Industry is undergoing a paradigm shift driven by regulatory changes, technological innovation, and sustainability imperatives. Amidst intense demand growth from diverse end-users, companies are focusing on new product launches to cater to individual applications. Companies are also emphasizing operational resilience and circular economy principles and are aligning strategies to secure long-term growth. The report identifies key structural changes, disruptive technologies, and evolving trade flows influencing competitiveness, helping stakeholders strengthen decision-making for both the short and long term.

What are the Biggest Opportunities for Growth in the Dementia and Movement Disorder Treatment Industry?
The Dementia and Movement Disorder Treatment Market sector has shown strong adaptability amid volatility in prices, supply chain disruptions, and geopolitical tensions. Moving forward, potential opportunities lie in niche products, aggressive distribution activities, and digital process optimization. With increasing demand from emerging markets, Dementia and Movement Disorder Treatment Market is positioned for growth through 2030 and beyond. This chapter provides a strategic perspective for businesses to identify revenue-generating avenues, mitigate risks, and adopt innovative pathways for expansion.

Dementia and Movement Disorder Treatment Market Segment Insights
The Dementia and Movement Disorder Treatment Industry offers diverse opportunities across product types, applications, and distribution channels. The analytical report provides detailed forecasts across diverse segments including By Application (Movement disorders, Progressive dementia, Progressive dementia with neurological abnormality (PDNA)), By Drug Class (MAO inhibitors, Acetylcholinesterase inhibitors, Glutamate inhibitors, Others). Insights cover the largest and fastest-growing product types, applications, and regions, highlighting drivers behind each segment. Market outlooks are provided for five regions—Asia Pacific, North America, Europe, South America, and Middle East & Africa—with country-level forecasts for 22 markets through 2032.

Dementia and Movement Disorder Treatment Industry Value Chain
The chapter identifies potential companies and their operations across the global Dementia and Movement Disorder Treatment Industry ecosystem. It assists decision-makers in evaluating global Dementia and Movement Disorder Treatment Market fundamentals, market dynamics, and disruptive trends across the value chain segments. According to the International Council of Chemical Associations (ICCA), chemicals underpin over 95% of manufactured products worldwide.

Scenario Analysis and Forecasts
Strategic planning in the Dementia and Movement Disorder Treatment Industry requires resilience to uncertain macroeconomic and regulatory conditions. To guide stakeholders, the report offers three scenario forecasts—low growth, reference case, and high growth—enabling companies to align strategies under different market conditions.

Asia Pacific Dementia and Movement Disorder Treatment Market Analysis – Hub of Industrial Transformation
Asia Pacific continues to be the largest and fastest-growing region for Dementia and Movement Disorder Treatment Market, underpinned by rapid industrialization, large-scale infrastructure development, and rising consumption across emerging economies. China, India, and Southeast Asia lead the demand surge, supported by investments in chemical parks, free trade agreements, and rising domestic manufacturing capacity. China remains the single largest producer and consumer of chemicals, accounting for over $1.5 trillion in chemical sales, followed by India, which is projected by the India Brand Equity Foundation (IBEF) to become a $300 billion chemicals market by 2025. Further, Japanese and South Korean markets remain stable with most companies focusing on new product launches and diversification of sales channels.

United States Dementia and Movement Disorder Treatment Market Insights – Innovation and Specialty Leadership
The American Chemistry Council (ACC) projects steady annual demand growth for specialty and performance chemicals, particularly in automotive, electronics, agriculture, and construction applications. The US continues to lead in specialty and high-value-added chemicals, with investments focused on R&D, advanced process technologies, and digital manufacturing. In addition, the Canadian and Mexican markets offer lucrative growth pockets for manufacturers and vendors. Focus on private-brand offerings and promotions, diversified sales channels, expansion into niche segments, adoption of advanced technologies, and sustainability are widely observed across the North American Dementia and Movement Disorder Treatment Market.

Europe Dementia and Movement Disorder Treatment Market Outlook 2025 – Regulatory and Innovation-Driven Growth
Europe is one of the largest markets for Dementia and Movement Disorder Treatment Market with demand from both Western Europe and Eastern European regions increasing over the medium to long-term future. The European chemical sector employs more than 1.2 million people directly and is highly influenced by the EU Green Deal, which aims for climate neutrality by 2050. With increasing adoption of advanced technologies, raw materials, and digital transformation, Europe remains a strategic hub for Dementia and Movement Disorder Treatment Industry competitiveness. The report analyses the key Dementia and Movement Disorder Treatment Market drivers and opportunities across Germany, France, the United Kingdom, Spain, Italy, Russia, and other Europe.

Latin American Dementia and Movement Disorder Treatment Market outlook rebounds in line with economic growth
Optimistic economic outlook across Brazil, Argentina, Chile, and other South and Central American countries presents strong opportunities for domestic and international Dementia and Movement Disorder Treatment Market companies. Increased consumer spending is estimated across markets over the next few quarters through 2026. Expanding trade partnerships, urbanization, and growing demand for specialty products underpin market prospects.

Middle East and Africa Dementia and Movement Disorder Treatment Markets- New Opportunities for Companies Harnessing Diversity
The Middle East remains a key hub for Dementia and Movement Disorder Treatment Market companies, with Saudi Arabia, UAE, and Qatar investing heavily in distribution networks. In addition, Africa presents strong growth potential in Nigeria, South Africa, and other emerging economies, with increasing demand for cost effective and accessible products. Investment strategies tailored to localized needs and sustainable growth will be crucial for success. In addition to Nigeria, Algeria, South Africa, and other markets, steady growth markets in Ethiopia, Rwanda, Ghana, Tanzania, the Democratic Republic of Congo, and others present significant prospects for companies.

Competitive Landscape – How Dementia and Movement Disorder Treatment Market Companies Outcompete in 2025
The ability to adapt to changing regulations, sustainability imperatives, and customer-specific innovations defines leadership in the Dementia and Movement Disorder Treatment Market. Companies are leveraging M&A activities, strategic joint ventures, and vertical integration to secure raw material access and strengthen downstream presence. The report profiles leading players, analyzing their 2024 revenues, market shares, R&D expenditures, and strategic directions. The report analyzes Acorda Therapeutics Inc, Amneal Pharmaceuticals Inc, Bausch Health Companies Inc, Biogen Inc, Eisai Co. Ltd, GlaxoSmithKline Plc, H Lundbeck AS, Johnson and Johnson, Kirin Holdings Co. Ltd, Lannett Co. Inc, Merck and Co. Inc, Neurocrine Biosciences Inc, Novartis AG, Organon and Co., Orion Pharma Ltd, Otsuka Holdings Co. Ltd, Supernus Pharmaceuticals Inc, Teva Pharmaceutical Industries Ltd, UCB SA. Each company is benchmarked through a detailed SWOT and financial analysis, providing clients with insights into competitive positioning and innovation leadership.

Dementia and Movement Disorder Treatment Market Scope
Leading Segments
By Application
Movement disorders
Progressive dementia
Progressive dementia with neurological abnormality (PDNA)
By Drug Class
MAO inhibitors
Acetylcholinesterase inhibitors
Glutamate inhibitors
Others

Leading Companies
Acorda Therapeutics Inc
Amneal Pharmaceuticals Inc
Bausch Health Companies Inc
Biogen Inc
Eisai Co. Ltd
GlaxoSmithKline Plc
H Lundbeck AS
Johnson and Johnson
Kirin Holdings Co. Ltd
Lannett Co. Inc
Merck and Co. Inc
Neurocrine Biosciences Inc
Novartis AG
Organon and Co.
Orion Pharma Ltd
Otsuka Holdings Co. Ltd
Supernus Pharmaceuticals Inc
Teva Pharmaceutical Industries Ltd
UCB SA

Geographies
North America- US, Canada, Mexico
Europe- Germany, France, UK, Spain, Italy, Nordics, BeNeLux, Others
Asia Pacific- China, India, Japan, South Korea, Australia, South East Asia, Others
Latin America- Brazil, Argentina, Others
Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Reasons to Buy the Report
  • Make informed decisions with 12-year forecasts across 22 countries and multiple market segments.
  • Evaluate regulatory impacts, sustainability trends, and disruptive technologies shaping the chemicals industry.
  • Gain insights into the competitive landscape, including company profiles, financials, and strategic moves.
  • Build an integrated understanding of the chemicals ecosystem across upstream, midstream, and downstream operations.
  • Leverage insights on circular economy initiatives, digitalization, and carbon-neutral strategies driving the next decade.
  • Assess risks and opportunities with scenario-based forecasts tailored to different growth conditions.
  • Access the report in multiple formats (PDF, Excel, PPT) for easier integration into strategic planning.

    • Table of Contents

    181 Pages
    1. Table of Contents
    List of Figures and Tables
    2. Executive Summary
    2.1 Key Highlights
    2.1.1 Dementia and Movement Disorder Treatment Market Size Outlook, 2018-2024 and 2025-2032
    2.1.2 Largest Dementia and Movement Disorder Treatment Market Types and Applications
    2.1.3 Fastest Growing Segments
    2.1.4 Potential Markets
    2.1.5 Market Concentration
    2.2 Market Scope and Segmentation
    2.2.1 Market Scope- Segments
    2.2.2 Market Scope- Countries
    2.2.3 Macroeconomic and Demographic Outlook
    2.2.4 Abbreviations
    2.2.5 Units and Currency Conversions
    3. Research Methodology
    3.1 Primary Research Surveys
    3.2 Secondary Data Sources
    3.3 Data Triangulation
    3.4 Forecast Methodology
    3.5 Assumptions and Limitations
    4. Introduction to Global Dementia and Movement Disorder Treatment Market in 2025
    4.1 Industry Panorama
    4.2 Leading Companies Profiled in the Study
    4.3 Asia Pacific Markets offer Robust Market Prospects for New Entrants
    4.4 Market Dynamics
    4.4.1 Market Dynamics- Trends and Drivers
    4.4.2 Market Dynamics- Opportunities and Challenges
    4.5 Regional Analysis
    4.6 Porter’s Five Force Analysis
    4.6.1 Intensity of Competitive Rivalry
    4.6.2 Threat of New Entrants
    4.6.3 Threat of Substitutes
    4.6.4 Bargaining Power of Buyers
    4.6.5 Bargaining Power of Suppliers
    4.7 Dementia and Movement Disorder Treatment Market Industry Value Chain Analysis
    4.7.1 Stage of Value Chain
    4.7.2 Key Activities of Companies
    4.7.3 Companies Included in Each Stage
    4.7.4 Key Insights
    5. Dementia and Movement Disorder Treatment Market Outlook to 2032
    5.1 Market Size Forecast by Type, 2021-2024 and 2025-2032
    5.2 Market Size Forecast by Application, 2021-2024 and 2024-2032
    5.3 Market Size Forecast by Geography, 2021-2024 and 2024-2032
    By Application
    Movement disorders
    Progressive dementia
    Progressive dementia with neurological abnormality (PDNA)
    By Drug Class
    MAO inhibitors
    Acetylcholinesterase inhibitors
    Glutamate inhibitors
    Others
    6. Global Dementia and Movement Disorder Treatment Market Outlook across Growth Scenarios
    6.1 Low Growth Scenario
    6.2 Base/Reference Case
    6.3 High Growth Scenario
    6. North America Dementia and Movement Disorder Treatment Market Size Outlook
    6.1 Key Market Statistics, 2024
    6.2 North America Dementia and Movement Disorder Treatment Market Trends and Growth Opportunities
    6.2.1 North America Dementia and Movement Disorder Treatment Market Outlook by Type
    6.2.2 North America Dementia and Movement Disorder Treatment Market Outlook by Application
    6.3 North America Dementia and Movement Disorder Treatment Market Outlook by Country
    6.3.1 The US Dementia and Movement Disorder Treatment Market Outlook, 2021- 2032
    6.3.2 Canada Dementia and Movement Disorder Treatment Market Outlook, 2021- 2032
    6.3.3 Mexico Dementia and Movement Disorder Treatment Market Outlook, 2021- 2032
    7. Europe Dementia and Movement Disorder Treatment Market Size Outlook
    7.1 Key Market Statistics, 2024
    7.2 Europe Dementia and Movement Disorder Treatment Market Trends and Growth Opportunities
    7.2.1 Europe Dementia and Movement Disorder Treatment Market Outlook by Type
    7.2.2 Europe Dementia and Movement Disorder Treatment Market Outlook by Application
    7.3 Europe Dementia and Movement Disorder Treatment Market Outlook by Country
    7.3.2 Germany Dementia and Movement Disorder Treatment Market Outlook, 2021- 2032
    7.3.3 France Dementia and Movement Disorder Treatment Market Outlook, 2021- 2032
    7.3.4 The UK Dementia and Movement Disorder Treatment Market Outlook, 2021- 2032
    7.3.5 Spain Dementia and Movement Disorder Treatment Market Outlook, 2021- 2032
    7.3.6 Italy Dementia and Movement Disorder Treatment Market Outlook, 2021- 2032
    7.3.7 Russia Dementia and Movement Disorder Treatment Market Outlook, 2021- 2032
    7.3.8 Rest of Europe Dementia and Movement Disorder Treatment Market Outlook, 2021- 2032
    8. Asia Pacific Dementia and Movement Disorder Treatment Market Size Outlook
    8.1 Key Market Statistics, 2024
    8.2 Asia Pacific Dementia and Movement Disorder Treatment Market Trends and Growth Opportunities
    8.2.1 Asia Pacific Dementia and Movement Disorder Treatment Market Outlook by Type
    8.2.2 Asia Pacific Dementia and Movement Disorder Treatment Market Outlook by Application
    8.3 Asia Pacific Dementia and Movement Disorder Treatment Market Outlook by Country
    8.3.1 China Dementia and Movement Disorder Treatment Market Outlook, 2021- 2032
    8.3.2 India Dementia and Movement Disorder Treatment Market Outlook, 2021- 2032
    8.3.3 Japan Dementia and Movement Disorder Treatment Market Outlook, 2021- 2032
    8.3.4 South Korea Dementia and Movement Disorder Treatment Market Outlook, 2021- 2032
    8.3.5 Australia Dementia and Movement Disorder Treatment Market Outlook, 2021- 2032
    8.3.6 South East Asia Dementia and Movement Disorder Treatment Market Outlook, 2021- 2032
    8.3.7 Rest of Asia Pacific Dementia and Movement Disorder Treatment Market Outlook, 2021- 2032
    9. South America Dementia and Movement Disorder Treatment Market Size Outlook
    9.1 Key Market Statistics, 2024
    9.2 South America Dementia and Movement Disorder Treatment Market Trends and Growth Opportunities
    9.2.1 South America Dementia and Movement Disorder Treatment Market Outlook by Type
    9.2.2 South America Dementia and Movement Disorder Treatment Market Outlook by Application
    9.3 South America Dementia and Movement Disorder Treatment Market Outlook by Country
    9.3.1 Brazil Dementia and Movement Disorder Treatment Market Outlook, 2021- 2032
    9.3.2 Argentina Dementia and Movement Disorder Treatment Market Outlook, 2021- 2032
    9.3.3 Rest of South and Central America Dementia and Movement Disorder Treatment Market Outlook, 2021- 2032
    10. Middle East and Africa Dementia and Movement Disorder Treatment Market Size Outlook
    10.1 Key Market Statistics, 2024
    10.2 Middle East and Africa Dementia and Movement Disorder Treatment Market Trends and Growth Opportunities
    10.2.1 Middle East and Africa Dementia and Movement Disorder Treatment Market Outlook by Type
    10.2.2 Middle East and Africa Dementia and Movement Disorder Treatment Market Outlook by Application
    10.3 Middle East and Africa Dementia and Movement Disorder Treatment Market Outlook by Country
    10.3.1 Saudi Arabia Dementia and Movement Disorder Treatment Market Outlook, 2021- 2032
    10.3.2 The UAE Dementia and Movement Disorder Treatment Market Outlook, 2021- 2032
    10.3.3 Rest of Middle East Dementia and Movement Disorder Treatment Market Outlook, 2021- 2032
    10.3.4 South Africa Dementia and Movement Disorder Treatment Market Outlook, 2021- 2032
    10.3.5 Egypt Dementia and Movement Disorder Treatment Market Outlook, 2021- 2032
    10.3.6 Rest of Africa Dementia and Movement Disorder Treatment Market Outlook, 2021- 2032
    11. Company Profiles
    11.1 Leading 10 Companies
    Acorda Therapeutics Inc
    Amneal Pharmaceuticals Inc
    Bausch Health Companies Inc
    Biogen Inc
    Eisai Co. Ltd
    GlaxoSmithKline Plc
    H Lundbeck AS
    Johnson and Johnson
    Kirin Holdings Co. Ltd
    Lannett Co. Inc
    Merck and Co. Inc
    Neurocrine Biosciences Inc
    Novartis AG
    Organon and Co.
    Orion Pharma Ltd
    Otsuka Holdings Co. Ltd
    Supernus Pharmaceuticals Inc
    Teva Pharmaceutical Industries Ltd
    UCB SA
    11.2 Overview
    11.3 Products and Services
    11.4 SWOT Profile
    12. Appendix
    12.1 Subscription Options
    12.2 Customization Options
    12.3 Publisher Details

    Pricing

    Currency Rates
    How Do Licenses Work?

    How Do Licenses Work?

    The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

    • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

    • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

    • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

    • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

    • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

    License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

    Head shot

    Questions or Comments?

    Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
    Chat Now
    Contact Us